CA2711262C - Dental composition comprising a basic amino acid for alleviating tooth sensitivity - Google Patents
Dental composition comprising a basic amino acid for alleviating tooth sensitivity Download PDFInfo
- Publication number
- CA2711262C CA2711262C CA2711262A CA2711262A CA2711262C CA 2711262 C CA2711262 C CA 2711262C CA 2711262 A CA2711262 A CA 2711262A CA 2711262 A CA2711262 A CA 2711262A CA 2711262 C CA2711262 C CA 2711262C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- fluoride
- baa
- dental
- ion source
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/20—Protective coatings for natural or artificial teeth, e.g. sealings, dye coatings or varnish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
- A61K8/21—Fluorides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
- A61Q11/02—Preparations for deodorising, bleaching or disinfecting dentures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/22—Gas releasing
- A61K2800/222—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
Abstract
The invention provides a method of treating sensitive teeth comprising attaching a sealant composition comprising a basic amino acid to a person's tooth and allowing the basic amino acid to be slowly released over time in order to reduce chrome and/or acute tooth sensitivity together with compositions and methods of use.
Description
DENTAL COMPOSITION COMPRISING A BASIC AMINO ACID FOR ALLEVIATING TOOTH
SENSITIVITY = =
100011. =
FIELD OF THE INVENTION
SENSITIVITY = =
100011. =
FIELD OF THE INVENTION
[0002] The present invention relates to tooth sealant (sensitivity alleviating) compositions comprising a basic amino acid in free or salt form that may be used to help prevent demineralization of teeth, alleviate pain and/or sensitivity of a patient's teeth, and provide other benefits. Sealants may include polymeric coatings, varnishes and foams to coat the teeth and/or dental device for extended periods.
BACKGROUND
BACKGROUND
[0003] Dental caries consist of demineralization of a tooth caused by bacteria. In the early stages of caries a white spot develops on the tooth and if the disease is not haltectand reversed, the enamel surface breaks down to form a lesion. This can then lead to decay and eventually, a fractured tooth. It is well known that development of dental caries May be reduced by means of various factors, such as diet and oral hygiene measures, anti-microbial treatments and the ' provision of fluoride to the teeth.
100041 Tooth sensitivity is also a common problem affecting children and adults. Generally, tooth sensitivity may be caused by gingival recession, dentine exposure due to erosion or abrasion, or periodontal surgery that includes root planning. ,Such conditions leave the dentinal tubules of the tissue susceptible to irritation by chemical, bacterial, mechanical or thermal = stimuli. Examples of stimuli include heat, cold, and sweet foods. It is believed that tooth sensitivity is the result of nerve endings of the dental pulp being excited by fluid flow through =
the exposed dentinal tubules.
100051 Treatments directed to alleviating pain associated with sensitive teeth have. generally focused on blocking access to the dentinal tubules so as to prevent stimuli from causing pain and sensitivity. Many treatments have been developed which include application of inorganic or = organic components designed to plug or otherwise block dentinal tubules for a limited time: A
disadvantage, of such treatments is that normal habits such as 'eating certain foods (e.g., foods = with a high acid content) or brushing can negate the treatment. Recently, testing has revealed that increased fluoride levels within the mouth may also be used as a treatment for tooth sensitivity (Toumba and Andreadis).
=
=
[00061 Current methods for administering fluoride for caries prevention include the fluoridation of drinking water, the ingestion of fluoride tablets, the incorporation of fluoride into mouth washes, toothpastes, and foods, the topical application of fluoride solutions, gels and varnishes and recently, the incorporation of fluoride in dental materials and devices.
100071 Evidence supports the concept of frequent applications of relatively low concentrations of fluoride ions for the prevention of caries and the treatment of sensitive teeth. A sustained and controlled release delivery system could help to achieve this goal.
100081 Arginine and other basic amino acids have been proposed for use in oral care and are believed to have significant benefits in combating cavity formation and tooth sensitivity.
Combining these basic amino acids with minerals having oral care benefits, e.g., fluoride and calcium, to form an oral care product having acceptable long term stability, however, has proven challenging. Partly because of unaddressed formulation hurdles and partly because arginine has generally been viewed in the art as a potential alternative to fluoride rather than a co-active, there has been little motivation to make oral care products comprising both arginine and fluoride.
Additional hurdles are potentially posed by addition of an antimicrobial agent. Commercially available arginine-based toothpaste, such as ProClude* and DenChide , for example, contain arginine bicarbonate and calcium carbonate, but not .fluoride nor any antimicrobial agent.
BRIEF SUMMARY OF THE INVENTION
100091 In one embodiment, the invention provides a dental sealant composition comprising a basic amino acid in free or salt foiiii (SAM. The sealant composition additionally may comprise fluoride. The BAA is preferably arginine, in free or orally acceptable salt form..
100101 in another embodiment, the present invention relates to a method of treating sensitive teeth with a basic amino acid in free or salt form (BAA) in a sealant composition, preferably in the presence of fluoride. The method involves: (1) attaching a BAA-releasing sealant composition to a person's tooth; and (2) allowing a BAA to be slowly released over time in order to reduce chronic and/or acute tooth sensitivity. Preferably, the sealant acts also as a fluoride releasing composition as well. Because the method relies on release of a BAA
into the oral cavity, the method also prevents future pain associated with dental caries by preventing dem.i.neralization and maintaining strong enamel.
[00111 The invention further provides methods to improve oral health comprising use of a dental sealant composition comprising a BAA., e.g., by a subject in need thereof, to a. reduce or inhibit formation of dental caries, b. reduce, repair or inhibit early enamel lesions, c. reduce or inhibit demineralization and promote remineralization of the teeth, d. reduce hypersensitivity of the teeth, e. reduce or inhibit gingivitis, f. promote healing of sores or cuts in the mouth, g. reduce levels of acid producing bacteria, it to increase relative levels of arginolytic bacteria, i. inhibit microbial biofilm formation in the oral cavity, j. raise andlor maintain plaque pH at levels of at least pH 5.5 following sugar challenge, k. reduce plaque accumulation, I. treat dry mouth, in. whiten teeth, n. enhance systemic health, including cardiovascular health, e.g., by reducing potential for systemic infection via the oral tissues, o. reduce erosion of the teeth, p. immunize the teeth against cariogenic bacteria, andlor q. clean the teeth and oral cavity.
100121 The invention further provides the use of a BAA in the manufacture of a dental sealant, e.g., for use in a method of treating sensitive teeth, or in any of the methods set forth above.
100131 The sealant compositions may be used for alleviating pain and/or sensitivity of teeth in addition to any effect that the BAA releasing sealant compositions may have in preventing dental caries. The compositions may be attached to a tooth to provide slow-BAA
releasing devices for releasing a BAA into the saliva of an individual.
100141 The daily dissolution rate (DDR) of the composition under conditions in the mouth may range from about 0.1 to about 100 % per day. The required DDR of the. sealant composition will depend upon the duration of BAA. release required. For example, if the composition is required to release a BAA over a long period, such as 1-2 years, the DDR is preferably about 0.1 to about 0.5 %. However, if a BAA need only be released fbr a shorter period, such as a few hours, days, weeks, or months, a faster releasing sealant may be used, for example having a DDR of up to about 100%.
By "dental sealant composition" is meant a composition which attaches to the teeth. The compositions may be applied as a spray, for example using a hydrocarbon propellant.
Alternatively, the compositions comprise a polymer or varnish suitable for painting onto teeth.
Alternatively, the compositions may be incorporated into dental cement or filling materials.
For example, the compositions may be attached to a tooth, for example being attached to rear molar using standard dental cement or as a powder for adding to dental materials, such as dental amalgams, thereby providing means to supplement a BAA release into saliva to assist in the prevention or reduction of dental caries. The powder may be included in a number of other dental materials, such as fissure sealant resins or composite bonding materials to cement bonds and brackets in orthodontic appliances. Powder applications may use sealant compositions that have a lower DDR than those that are attached directly to a tooth, for example having a DDR of about 0.1 to about 1%.
[0014a] Specific aspects of the invention include:
a tooth sensitivity alleviating composition comprising a basic amino acid in free or salt form (BAA) and a fluoride ion source, wherein the composition has a daily dissolution rate, under conditions in a mouth in the range of about 0.1 to about 100%;
the composition as described herein, wherein the composition is in pellet form, attachable to a tooth using dental cement;
a tooth sensitivity alleviating composition comprising a basic amino acid in free or salt form (BAA) and fluoride ion source, wherein the composition has a daily dissolution rate under conditions in a mouth of from about 0.1 to about 100%, wherein said fluoride ion source is present at a concentration of at least about 12 percent, by weight, of the composition and is selected from the group consisting of stannous fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride, aluminum fluoride, sodium
100041 Tooth sensitivity is also a common problem affecting children and adults. Generally, tooth sensitivity may be caused by gingival recession, dentine exposure due to erosion or abrasion, or periodontal surgery that includes root planning. ,Such conditions leave the dentinal tubules of the tissue susceptible to irritation by chemical, bacterial, mechanical or thermal = stimuli. Examples of stimuli include heat, cold, and sweet foods. It is believed that tooth sensitivity is the result of nerve endings of the dental pulp being excited by fluid flow through =
the exposed dentinal tubules.
100051 Treatments directed to alleviating pain associated with sensitive teeth have. generally focused on blocking access to the dentinal tubules so as to prevent stimuli from causing pain and sensitivity. Many treatments have been developed which include application of inorganic or = organic components designed to plug or otherwise block dentinal tubules for a limited time: A
disadvantage, of such treatments is that normal habits such as 'eating certain foods (e.g., foods = with a high acid content) or brushing can negate the treatment. Recently, testing has revealed that increased fluoride levels within the mouth may also be used as a treatment for tooth sensitivity (Toumba and Andreadis).
=
=
[00061 Current methods for administering fluoride for caries prevention include the fluoridation of drinking water, the ingestion of fluoride tablets, the incorporation of fluoride into mouth washes, toothpastes, and foods, the topical application of fluoride solutions, gels and varnishes and recently, the incorporation of fluoride in dental materials and devices.
100071 Evidence supports the concept of frequent applications of relatively low concentrations of fluoride ions for the prevention of caries and the treatment of sensitive teeth. A sustained and controlled release delivery system could help to achieve this goal.
100081 Arginine and other basic amino acids have been proposed for use in oral care and are believed to have significant benefits in combating cavity formation and tooth sensitivity.
Combining these basic amino acids with minerals having oral care benefits, e.g., fluoride and calcium, to form an oral care product having acceptable long term stability, however, has proven challenging. Partly because of unaddressed formulation hurdles and partly because arginine has generally been viewed in the art as a potential alternative to fluoride rather than a co-active, there has been little motivation to make oral care products comprising both arginine and fluoride.
Additional hurdles are potentially posed by addition of an antimicrobial agent. Commercially available arginine-based toothpaste, such as ProClude* and DenChide , for example, contain arginine bicarbonate and calcium carbonate, but not .fluoride nor any antimicrobial agent.
BRIEF SUMMARY OF THE INVENTION
100091 In one embodiment, the invention provides a dental sealant composition comprising a basic amino acid in free or salt foiiii (SAM. The sealant composition additionally may comprise fluoride. The BAA is preferably arginine, in free or orally acceptable salt form..
100101 in another embodiment, the present invention relates to a method of treating sensitive teeth with a basic amino acid in free or salt form (BAA) in a sealant composition, preferably in the presence of fluoride. The method involves: (1) attaching a BAA-releasing sealant composition to a person's tooth; and (2) allowing a BAA to be slowly released over time in order to reduce chronic and/or acute tooth sensitivity. Preferably, the sealant acts also as a fluoride releasing composition as well. Because the method relies on release of a BAA
into the oral cavity, the method also prevents future pain associated with dental caries by preventing dem.i.neralization and maintaining strong enamel.
[00111 The invention further provides methods to improve oral health comprising use of a dental sealant composition comprising a BAA., e.g., by a subject in need thereof, to a. reduce or inhibit formation of dental caries, b. reduce, repair or inhibit early enamel lesions, c. reduce or inhibit demineralization and promote remineralization of the teeth, d. reduce hypersensitivity of the teeth, e. reduce or inhibit gingivitis, f. promote healing of sores or cuts in the mouth, g. reduce levels of acid producing bacteria, it to increase relative levels of arginolytic bacteria, i. inhibit microbial biofilm formation in the oral cavity, j. raise andlor maintain plaque pH at levels of at least pH 5.5 following sugar challenge, k. reduce plaque accumulation, I. treat dry mouth, in. whiten teeth, n. enhance systemic health, including cardiovascular health, e.g., by reducing potential for systemic infection via the oral tissues, o. reduce erosion of the teeth, p. immunize the teeth against cariogenic bacteria, andlor q. clean the teeth and oral cavity.
100121 The invention further provides the use of a BAA in the manufacture of a dental sealant, e.g., for use in a method of treating sensitive teeth, or in any of the methods set forth above.
100131 The sealant compositions may be used for alleviating pain and/or sensitivity of teeth in addition to any effect that the BAA releasing sealant compositions may have in preventing dental caries. The compositions may be attached to a tooth to provide slow-BAA
releasing devices for releasing a BAA into the saliva of an individual.
100141 The daily dissolution rate (DDR) of the composition under conditions in the mouth may range from about 0.1 to about 100 % per day. The required DDR of the. sealant composition will depend upon the duration of BAA. release required. For example, if the composition is required to release a BAA over a long period, such as 1-2 years, the DDR is preferably about 0.1 to about 0.5 %. However, if a BAA need only be released fbr a shorter period, such as a few hours, days, weeks, or months, a faster releasing sealant may be used, for example having a DDR of up to about 100%.
By "dental sealant composition" is meant a composition which attaches to the teeth. The compositions may be applied as a spray, for example using a hydrocarbon propellant.
Alternatively, the compositions comprise a polymer or varnish suitable for painting onto teeth.
Alternatively, the compositions may be incorporated into dental cement or filling materials.
For example, the compositions may be attached to a tooth, for example being attached to rear molar using standard dental cement or as a powder for adding to dental materials, such as dental amalgams, thereby providing means to supplement a BAA release into saliva to assist in the prevention or reduction of dental caries. The powder may be included in a number of other dental materials, such as fissure sealant resins or composite bonding materials to cement bonds and brackets in orthodontic appliances. Powder applications may use sealant compositions that have a lower DDR than those that are attached directly to a tooth, for example having a DDR of about 0.1 to about 1%.
[0014a] Specific aspects of the invention include:
a tooth sensitivity alleviating composition comprising a basic amino acid in free or salt form (BAA) and a fluoride ion source, wherein the composition has a daily dissolution rate, under conditions in a mouth in the range of about 0.1 to about 100%;
the composition as described herein, wherein the composition is in pellet form, attachable to a tooth using dental cement;
a tooth sensitivity alleviating composition comprising a basic amino acid in free or salt form (BAA) and fluoride ion source, wherein the composition has a daily dissolution rate under conditions in a mouth of from about 0.1 to about 100%, wherein said fluoride ion source is present at a concentration of at least about 12 percent, by weight, of the composition and is selected from the group consisting of stannous fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride, aluminum fluoride, sodium
4 hydrogen fluoride, hydrogen fluoride, sodium fluoride, calcium fluoride, magnesium fluoride, and potassium fluoride, wherein the composition for incorporation into a dental material, and wherein said dental material is selected from the group consisting of a dental amalgam, a fissure sealant resin, a composite bonding material, an orthodontic appliance, a dental prosthetic, a resin varnish, and an oral surgery implant;
the composition as described herein for use in the treatment of sensitive teeth to reduce chronic and/or acute tooth sensitivity; and use of a basic amino acid in free or salt form in the manufacture of a tooth sensitivity alleviating composition.
[0015] These and other benefits, advantages and features of the present invention will become more fully apparent from the following description, or may be learned by the practice of the invention as set forth hereinafter.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] The inventive method involves attaching a BAA releasing sealant composition to a person's tooth, or a dental appliance, such as a denture, and then allowing a BAA to be slowly released over time in order to reduce chronic and/or acute tooth sensitivity.
According to a preferred embodiment, the BAA releasing sealant composition comprises about 5 to about 75 weight percent BAA and about 5 to about 30 weight percent fluorine.
[0017] Slow-release BAA devices consistently raise intra-oral salivary BAA
levels for periods up to 2 years or more, and now also appear to completely alleviate the symptoms of dentine sensitivity within two weeks, while maintaining the benefit for up to six months or more in adults. Subjects report complete alleviation of their dentine sensitivity. There are no adverse events reported or observed. There is a slight tendency for an increase in plaque and gingival indices, but this is non-significant.
[0018] The basic amino acids which can be used in the compositions and methods of the invention include not only naturally occurring basic amino acids, such as arginine, lysine, and 4a histidine, but also any basic amino acids having a carboxyl group and an amino group in the molecule, which are water-soluble and provide an aqueous solution with a pH of 7 or greater.
10019.1 Accordingly, basic amino acids include, but are not limited to, arginine, lysine, citrullene, omithine, ereatine, histidine, diaminobutanoic acid, diaminoproprionic acid, salts thereof or combinations thereof. In a particular embodiment, the basic amino acids are selected from arginine, citrullene, and omithine.
10201 In certain embodiments, the basic amino acid is arginine, for example, 1-arginine, or a salt thereof, for example arginine bicarbonate, arginine phosphate, or arginine hydrochloride.
[00211 The compositions of the invention are intended for consumption and so salts for use in the present invention should be safe for such use, in the amounts and concentrations provided.
Suitable salts include salts known in the art to be pharmaceutically acceptable salts are generally considered to be physiologically acceptable in the amounts and concentrations provided.
Physiologically acceptable salts include those derived from phaiinaceutically acceptable inorganic or organic acids or bases, for example acid addition salts formed by acids which form a physiological acceptable anion, e.g., hydrochloride or bromide salt, and base addition salts formed by bases which form a physiologically acceptable cation, for example those derived from alkali metals such as potassium and sodium or alkaline earth metals such as calcium and magnesium. Physiologically acceptable salts may be obtained using standard procedures known in the art, for example, by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
100221 The concentration of BAA will vary depending on the formulation. In one embodiment, the BAA (amount of salt expressed as weight of the free base) is 1 40 % by weight of the formulation, e.g. 5 20%, for example about 10%.
100231 The compositions of the invention may additionally comprise fluoride.
Representative fluoride ion sources include, but are not limited to, stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, amm.onium fluorosilicate, amine fluoride, ammonium fluoride, and combinations thereof in certain embodiments the fluoride ion source includes stannous fluoride, sodium fluoride, sodium monofluorophosphate as well as mixtures thereof. In a particular embodiment, the fluoride source is sodium fluoride or sodium monofluorophosphate. The fluoride may be present in the formulation in effective amounts, as = CA 02711262 2013-01-10 used in conventional dental sealants, e.g. higher than typically used in toothpaste. It may, for example be present, e.g., in an amount of about 2,500 ppm to about 250,000 ppm, expressed as level of fluoride ion, or in an amount of 2 --25%, for example, at least 12%, e.g., 15 - 25% by weight of the composition.
100241 The compositions may additionally comprise an antibacterial agent, such as triclosan, or an agent which inhibits attachment of bacteria.
100251 As used throughout, ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range.
In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls. It is understood that when formulations are described, they may be described in terms of their ingredients, as is common in the art, notwithstanding that these ingredients may rent with one another in the actual formulation as it is made, stored and used, and such products are intended to be covered by the formulations described.
100261 The following examples further describe and demonstrate illustrative embodiments within the scope of the present invention. The examples are given solely for illustration and are not to be construed as limitations of this invention as many variations are possible without departing from the scope thereof.
EXAMPLES =
Example 1 100271 Formulations comprising.10 wt % arginine bicarbonate are prepared as follows:
Ingredient - (Part 1) Water QS
Sodium Fluoride 2.65 Millie Acid 1.75 Sodium Mono phosphate 1.38 Sodium Methyl Cocoyl Taurate Flavor 0.6 Sodium Saccharin 0.35 =
=
=
Sodium Benzoate Arginine Bicarbonate 10 Total (Part!) 100 Part 2 Part 93 Hydrocarbon propellant mixture 7 Total 100 Example 2 100281 Varnish formulation comprising 10 wt % arginine hydrochloride is prepared as follows:
Ingredient Colophoniurn 2/.01 90% Ethyl Alcohol 27.87 Shellac 21.5 Mastic 11.82 Sodium Fluoride 4.98 Sodium Saccharin 0.68 'Raspbery Flavor 0.65 White Beeswax 0.48 A.rginine Hydrochloride 10 Total 100
the composition as described herein for use in the treatment of sensitive teeth to reduce chronic and/or acute tooth sensitivity; and use of a basic amino acid in free or salt form in the manufacture of a tooth sensitivity alleviating composition.
[0015] These and other benefits, advantages and features of the present invention will become more fully apparent from the following description, or may be learned by the practice of the invention as set forth hereinafter.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] The inventive method involves attaching a BAA releasing sealant composition to a person's tooth, or a dental appliance, such as a denture, and then allowing a BAA to be slowly released over time in order to reduce chronic and/or acute tooth sensitivity.
According to a preferred embodiment, the BAA releasing sealant composition comprises about 5 to about 75 weight percent BAA and about 5 to about 30 weight percent fluorine.
[0017] Slow-release BAA devices consistently raise intra-oral salivary BAA
levels for periods up to 2 years or more, and now also appear to completely alleviate the symptoms of dentine sensitivity within two weeks, while maintaining the benefit for up to six months or more in adults. Subjects report complete alleviation of their dentine sensitivity. There are no adverse events reported or observed. There is a slight tendency for an increase in plaque and gingival indices, but this is non-significant.
[0018] The basic amino acids which can be used in the compositions and methods of the invention include not only naturally occurring basic amino acids, such as arginine, lysine, and 4a histidine, but also any basic amino acids having a carboxyl group and an amino group in the molecule, which are water-soluble and provide an aqueous solution with a pH of 7 or greater.
10019.1 Accordingly, basic amino acids include, but are not limited to, arginine, lysine, citrullene, omithine, ereatine, histidine, diaminobutanoic acid, diaminoproprionic acid, salts thereof or combinations thereof. In a particular embodiment, the basic amino acids are selected from arginine, citrullene, and omithine.
10201 In certain embodiments, the basic amino acid is arginine, for example, 1-arginine, or a salt thereof, for example arginine bicarbonate, arginine phosphate, or arginine hydrochloride.
[00211 The compositions of the invention are intended for consumption and so salts for use in the present invention should be safe for such use, in the amounts and concentrations provided.
Suitable salts include salts known in the art to be pharmaceutically acceptable salts are generally considered to be physiologically acceptable in the amounts and concentrations provided.
Physiologically acceptable salts include those derived from phaiinaceutically acceptable inorganic or organic acids or bases, for example acid addition salts formed by acids which form a physiological acceptable anion, e.g., hydrochloride or bromide salt, and base addition salts formed by bases which form a physiologically acceptable cation, for example those derived from alkali metals such as potassium and sodium or alkaline earth metals such as calcium and magnesium. Physiologically acceptable salts may be obtained using standard procedures known in the art, for example, by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
100221 The concentration of BAA will vary depending on the formulation. In one embodiment, the BAA (amount of salt expressed as weight of the free base) is 1 40 % by weight of the formulation, e.g. 5 20%, for example about 10%.
100231 The compositions of the invention may additionally comprise fluoride.
Representative fluoride ion sources include, but are not limited to, stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, amm.onium fluorosilicate, amine fluoride, ammonium fluoride, and combinations thereof in certain embodiments the fluoride ion source includes stannous fluoride, sodium fluoride, sodium monofluorophosphate as well as mixtures thereof. In a particular embodiment, the fluoride source is sodium fluoride or sodium monofluorophosphate. The fluoride may be present in the formulation in effective amounts, as = CA 02711262 2013-01-10 used in conventional dental sealants, e.g. higher than typically used in toothpaste. It may, for example be present, e.g., in an amount of about 2,500 ppm to about 250,000 ppm, expressed as level of fluoride ion, or in an amount of 2 --25%, for example, at least 12%, e.g., 15 - 25% by weight of the composition.
100241 The compositions may additionally comprise an antibacterial agent, such as triclosan, or an agent which inhibits attachment of bacteria.
100251 As used throughout, ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range.
In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls. It is understood that when formulations are described, they may be described in terms of their ingredients, as is common in the art, notwithstanding that these ingredients may rent with one another in the actual formulation as it is made, stored and used, and such products are intended to be covered by the formulations described.
100261 The following examples further describe and demonstrate illustrative embodiments within the scope of the present invention. The examples are given solely for illustration and are not to be construed as limitations of this invention as many variations are possible without departing from the scope thereof.
EXAMPLES =
Example 1 100271 Formulations comprising.10 wt % arginine bicarbonate are prepared as follows:
Ingredient - (Part 1) Water QS
Sodium Fluoride 2.65 Millie Acid 1.75 Sodium Mono phosphate 1.38 Sodium Methyl Cocoyl Taurate Flavor 0.6 Sodium Saccharin 0.35 =
=
=
Sodium Benzoate Arginine Bicarbonate 10 Total (Part!) 100 Part 2 Part 93 Hydrocarbon propellant mixture 7 Total 100 Example 2 100281 Varnish formulation comprising 10 wt % arginine hydrochloride is prepared as follows:
Ingredient Colophoniurn 2/.01 90% Ethyl Alcohol 27.87 Shellac 21.5 Mastic 11.82 Sodium Fluoride 4.98 Sodium Saccharin 0.68 'Raspbery Flavor 0.65 White Beeswax 0.48 A.rginine Hydrochloride 10 Total 100
Claims (21)
1. A tooth sensitivity alleviating composition comprising a basic amino acid in free or salt form (BAA) and a fluoride ion source, wherein the composition has a daily dissolution rate under conditions in a mouth in the range of about 0.1 to about 100%.
2. The composition of claim 1, wherein the BAA comprises arginine, in free or salt form.
3. The composition of claim 1 or 2, wherein the fluoride ion source is aluminum fluoride, sodium hydrogen fluoride, sodium fluoride, calcium fluoride, magnesium fluoride, or potassium fluoride.
4. The composition of any one of claims 1 to 3, wherein the fluoride ion source is present in an amount of at least about 12 percent by weight in the composition.
5. The composition of any one of claims 1 to 4, wherein the fluoride ion source is present in an amount of about 15 to about 25 percent by weight in the composition.
6. The composition of any one of claims 1 to 5, wherein the composition has a daily dissolution rate under conditions in a mouth in the range of about 0.1 to about 0.5%.
7. The composition of any one of claims 1 to 6, wherein the composition is in a powder form.
8. The composition of any one of claims 1 to 7, wherein the composition is for incorporation into a dental material selected from the group consisting of a dental amalgam, a fissure sealant resin, a composite bonding material, an orthodontic appliance, a dental prosthetic, a resin varnish, and an oral surgery implant.
9. The composition of claim 7, wherein the composition further comprises powder grains having a grain size of less than about 38 microns.
10. The composition of claim 7, wherein the composition further comprises powder grains having a grain size of less than about 106 microns.
11. The composition of any one of claims 1 to 6, wherein the composition is in pellet form, attachable to a tooth using dental cement.
12. A tooth sensitivity alleviating composition comprising a basic amino acid in free or salt form (BAA) and a fluoride ion source, wherein the composition has a daily dissolution rate under conditions in a mouth of from about 0.1 to about 100%, wherein said fluoride ion source is present at a concentration of at least about 12 percent, by weight, of the composition and is selected from the group consisting of stannous fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride, aluminum fluoride, sodium hydrogen fluoride, sodium fluoride, calcium fluoride, magnesium fluoride, and potassium fluoride, wherein the composition is for incorporation into a dental material, and wherein said dental material is selected from the group consisting of a dental amalgam, a fissure sealant resin, a composite bonding material, an orthodontic appliance, a dental prosthetic, a resin varnish, and an oral surgery implant.
13. The composition of claim 12 wherein the BAA comprises arginine.
14. The composition of claim 12 or 13, wherein the composition has a daily dissolution rate under conditions in a mouth of from about 0.1 to about 0.5%.
15. The composition of any one of claims 12 to 14, wherein the composition is in a powder form.
16. The composition of any one of claims 12 to 15, wherein the BAA is the form of a potassium salt.
17. The composition of any one of claims 12 to 15, wherein the BAA is in the form of a potassium hydrochloride salt or a potassium bromide salt.
18. The composition of any one of claims 12 to 15, wherein the fluoride ion source is potassium fluoride.
19. The composition as defined in any one of claims 1 to 18 for use in the treatment of sensitive teeth to reduce chronic and/or acute tooth sensitivity.
20. The composition of claim 19, wherein the composition is for adhesion to a tooth of a person in need thereof, thereby allowing BAA to be slowly released over time in order to reduce chronic and/or acute tooth sensitivity.
21. Use of a basic amino acid in free or salt form in the manufacture of a tooth sensitivity alleviating composition.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2742508P | 2008-02-08 | 2008-02-08 | |
| US61/027,425 | 2008-02-08 | ||
| PCT/US2009/033312 WO2009100283A2 (en) | 2008-02-08 | 2009-02-06 | Tooth sealant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2711262A1 CA2711262A1 (en) | 2009-08-13 |
| CA2711262C true CA2711262C (en) | 2015-06-23 |
Family
ID=40952706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2711262A Expired - Fee Related CA2711262C (en) | 2008-02-08 | 2009-02-06 | Dental composition comprising a basic amino acid for alleviating tooth sensitivity |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10391038B2 (en) |
| EP (1) | EP2249764B1 (en) |
| JP (2) | JP2011510095A (en) |
| CN (1) | CN101938970A (en) |
| AR (1) | AR070589A1 (en) |
| AU (1) | AU2009212339B2 (en) |
| BR (1) | BRPI0907103A2 (en) |
| CA (1) | CA2711262C (en) |
| CO (1) | CO6241091A2 (en) |
| MX (1) | MX2010007738A (en) |
| RU (1) | RU2493812C2 (en) |
| TW (1) | TWI376237B (en) |
| WO (1) | WO2009100283A2 (en) |
| ZA (1) | ZA201003694B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102406403A (en) * | 2011-12-19 | 2012-04-11 | 吴江市江南不锈钢器材有限责任公司 | Cup casing |
| US9107838B2 (en) | 2012-04-25 | 2015-08-18 | Therametrics Technologies, Inc. | Fluoride varnish |
| ES2707880T3 (en) * | 2012-09-07 | 2019-04-05 | Ivoclar Vivadent Ag | Varnish containing fluoride for application to the dental surface |
| CA2901431C (en) | 2013-02-15 | 2017-10-17 | Dentsply International Inc. | Dental varnish compositions comprising rosin, resin, and a fluoridizing agent |
| WO2016101158A1 (en) * | 2014-12-24 | 2016-06-30 | Colgate-Palmolive Company | Oral care composition |
| US10512668B2 (en) * | 2014-12-29 | 2019-12-24 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for delivering lypophilic agents to dental pulp and for enhancing dentin production |
| CN104758311A (en) * | 2015-04-24 | 2015-07-08 | 杭州维瓦科技有限公司 | Compound for treating hemodia and preparation method thereof |
| US20180243175A1 (en) * | 2015-09-10 | 2018-08-30 | The University Of Florida Research Foundation, Inc. | Arginine-containing restorative dental materials and methods of preventing and controlling caries associated with dental work |
| CN106361579A (en) * | 2016-11-10 | 2017-02-01 | 李雨阳 | Production method of tooth surface self-cleaning anti-adhesion coating |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3932608A (en) | 1971-08-30 | 1976-01-13 | General Mills, Inc. | Food composition |
| US3943241A (en) | 1971-08-30 | 1976-03-09 | General Mills, Inc. | Cariostatic composition |
| US3932605A (en) | 1972-06-12 | 1976-01-13 | Jaroslav Vit | Dental treatment |
| US3988434A (en) | 1972-08-07 | 1976-10-26 | Schole Murray L | Dental preparation |
| US4025616A (en) | 1973-03-06 | 1977-05-24 | The Procter & Gamble Company | Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies |
| US4100269A (en) | 1973-06-28 | 1978-07-11 | Lever Brothers Company | Anticalculus dentifrice |
| US4022880A (en) | 1973-09-26 | 1977-05-10 | Lever Brothers Company | Anticalculus composition |
| US3925543A (en) | 1973-11-01 | 1975-12-09 | Colgate Palmolive Co | Antibacterial oral compositions containing preservative-antioxidants |
| US4011309A (en) | 1975-01-20 | 1977-03-08 | Marion Laboratories, Inc. | Dentifrice composition and method for desensitizing sensitive teeth |
| US3954457A (en) * | 1975-04-28 | 1976-05-04 | Gary Maurice Weikel | Dental amalgam |
| US4064138A (en) | 1975-11-12 | 1977-12-20 | General Mills, Inc. | Amino acid derivatives |
| USRE31181E (en) | 1976-06-18 | 1983-03-15 | Means and method for improving natural defenses against caries | |
| ZA773318B (en) | 1976-06-18 | 1978-04-26 | I Kleinberg | Means and method for improving natural defenses against caries |
| US4108979A (en) | 1976-08-02 | 1978-08-22 | Indiana University Foundation | Dentifrice preparations comprising aluminum and a compatible abrasive |
| US4108981A (en) | 1976-08-02 | 1978-08-22 | Indiana University Foundation | Alkaline oral compositions comprising aluminum and a carboxylic acid |
| US4042680A (en) | 1976-08-02 | 1977-08-16 | Indiana University Foundation | Anticariogenic maloaluminate complexes |
| JPS5367290A (en) * | 1976-11-16 | 1978-06-15 | Sankin Ind Co | Hydraulic cement for dental treatment |
| US4146607A (en) | 1977-11-07 | 1979-03-27 | Lever Brothers Company | Synergistic anti-plaque mixture with tetradecylamine plus aluminum and/or zinc |
| US4160821A (en) | 1978-02-27 | 1979-07-10 | Johnson & Johnson | Treatment for gingivitis |
| US4213961A (en) | 1978-03-23 | 1980-07-22 | Beecham, Inc. | Oral compositions |
| GB1573727A (en) | 1978-05-19 | 1980-08-28 | Colgate Palmolive Co | Dentifrices |
| US4216961A (en) * | 1978-08-04 | 1980-08-12 | Mcquillan Mary J | Table baseball apparatus |
| JPS5569549A (en) * | 1978-11-16 | 1980-05-26 | Nitto Boseki Co Ltd | Novel substrate for determination of enzyme activity |
| US4225579A (en) | 1979-02-27 | 1980-09-30 | Israel Kleinberg | Means and method for improving defenses against caries |
| US4339432A (en) | 1979-06-20 | 1982-07-13 | Lever Brothers Company | Oral mouthwash containing zinc and glycine |
| US4269822A (en) | 1979-07-20 | 1981-05-26 | Laclede Professional Products, Inc. | Antiseptic dentifrice |
| JPS5835965B2 (en) | 1979-07-31 | 1983-08-05 | ライオン株式会社 | Oral composition |
| JPS5846483B2 (en) | 1979-09-20 | 1983-10-17 | ライオン株式会社 | Oral composition |
| JPS5924129B2 (en) | 1980-12-11 | 1984-06-07 | 三金工業株式会社 | dental cement adhesive |
| US4532124A (en) | 1981-08-19 | 1985-07-30 | Development Finance Corporation Of New Zealand | Dental rinse |
| JPS58118509A (en) | 1981-12-29 | 1983-07-14 | Lion Corp | Composition for oral cavity |
| US4885155A (en) | 1982-06-22 | 1989-12-05 | The Procter & Gamble Company | Anticalculus compositions using pyrophosphate salt |
| US4477429A (en) * | 1982-08-26 | 1984-10-16 | Johnson & Johnson Products, Inc. | Oral compositions comprising N.sup.α -alkyl derivatives of arginine |
| US4499067A (en) * | 1982-08-26 | 1985-02-12 | Johnson & Johnson Products, Inc. | Oral compositions comprising NG -acyl derivatives of arginine |
| US4725576A (en) | 1983-12-29 | 1988-02-16 | Research Foundation Of State University Of New York | Fungicidal polypeptide compositions containing L-histidine and methods for use therefore |
| US4528181A (en) | 1984-02-01 | 1985-07-09 | Colgate-Palmolive Company | Dentifrice containing dual sources of fluoride |
| US5334617A (en) | 1984-03-19 | 1994-08-02 | The Rockefeller University | Amino acids useful as inhibitors of the advanced glycosylation of proteins |
| GB8411731D0 (en) | 1984-05-09 | 1984-06-13 | Unilever Plc | Oral compositions |
| JPH0742219B2 (en) | 1984-07-26 | 1995-05-10 | ライオン株式会社 | Oral composition |
| US4538990A (en) | 1984-09-24 | 1985-09-03 | Medical College Of Ga. Research Institute, Inc. | Method of decreasing the permeability of a dental cavity |
| US4738722A (en) * | 1986-09-15 | 1988-04-19 | Den-Mat Corporation | Dental compositions incorporating glass ionomers |
| US5174989A (en) | 1987-11-25 | 1992-12-29 | Shiseido Company Ltd. | Oral composition |
| JPH01139524A (en) * | 1987-11-25 | 1989-06-01 | Shiseido Co Ltd | Composition for oral cavity |
| GB8729564D0 (en) | 1987-12-18 | 1988-02-03 | Unilever Plc | Oral compositions |
| US5438076A (en) | 1988-05-03 | 1995-08-01 | Perio Products, Ltd. | Liquid polymer composition, and method of use |
| JP2630640B2 (en) | 1988-11-15 | 1997-07-16 | 宇部興産株式会社 | Calcium phosphate cement pit fissure cold material |
| US5139768A (en) * | 1989-01-31 | 1992-08-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Dental composition for hypersensitive teeth |
| US5096700A (en) | 1990-09-28 | 1992-03-17 | The Procter & Gamble Company | Halogenated aminohexanoates and aminobutyrates antimicrobial agents |
| DE4110796A1 (en) | 1991-04-04 | 1992-10-08 | Bayer Ag | PROVISIONAL FASTENING MATERIALS |
| US5370865A (en) | 1992-05-15 | 1994-12-06 | Kao Corporation | Composition for use in oral cavity |
| US5286480A (en) | 1992-06-29 | 1994-02-15 | The Procter & Gamble Company | Use of N-acetylated amino acid complexes in oral care compositions |
| US5369142A (en) | 1993-01-15 | 1994-11-29 | The Ohio State University | Water soluble polymers containing amino acid residues for dental restoratives |
| US5505933A (en) * | 1994-06-27 | 1996-04-09 | Colgate Palmolive Company | Desensitizing anti-tartar dentifrice |
| EP0704533A1 (en) * | 1994-09-30 | 1996-04-03 | Bayer Ag | An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus |
| DE4445266A1 (en) * | 1994-12-19 | 1996-06-20 | Thera Ges Fuer Patente | Fluoride-releasing composite materials |
| WO1997002802A1 (en) * | 1995-07-10 | 1997-01-30 | Unilever N.V. | Self-heating dentifrice |
| US5747005A (en) | 1995-08-02 | 1998-05-05 | Barels; Ronald R. | Oil-based, anti-plaque dentifrice composition |
| US6036944A (en) | 1995-08-08 | 2000-03-14 | Enamelon, Inc. | Processes for the remineralization and mineralization of teeth |
| JPH0958053A (en) | 1995-08-29 | 1997-03-04 | Ricoh Co Ltd | Image forming apparatus |
| CA2184802C (en) * | 1995-10-10 | 2007-07-31 | Karl-Heinz Bender | Process for manufacture of imidazo benzodiazepine derivatives |
| US5895788A (en) * | 1996-01-31 | 1999-04-20 | The Board Of Trustees Of The University Of Arkansas | Use of L-arginine and salts thereof in drinking water for the prevention and/or treatment of pulmonary hypertension syndrome in avians |
| US5762911A (en) | 1996-03-05 | 1998-06-09 | The Research Foundation Of State University Of New York | Anti-caries oral compositions |
| US6488961B1 (en) | 1996-09-20 | 2002-12-03 | Ethypharm, Inc. | Effervescent granules and methods for their preparation |
| US5906811A (en) | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
| FR2768624B1 (en) * | 1997-09-25 | 1999-11-12 | Oreal | USE OF AN EXCITING AMINO ACID INHIBITOR IN A COSMETIC OR DERMATOLOGICAL COMPOSITION FOR SENSITIVE SKIN AND COMPOSITION OBTAINED |
| US5922346A (en) | 1997-12-01 | 1999-07-13 | Thione International, Inc. | Antioxidant preparation |
| US6805883B2 (en) | 1998-03-12 | 2004-10-19 | Mars, Incorporated | Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide |
| JP2000044422A (en) | 1998-07-31 | 2000-02-15 | Hironori Oka | Coating composition for tooth and its production |
| US5997301A (en) | 1998-10-20 | 1999-12-07 | Linden; Lars Ake | Treatment of tooth surfaces and substances therefor |
| US6166102A (en) * | 1998-12-08 | 2000-12-26 | Block Drug Company, Inc. | Denture adhesive |
| US6436370B1 (en) | 1999-06-23 | 2002-08-20 | The Research Foundation Of State University Of New York | Dental anti-hypersensitivity composition and method |
| GB2354441A (en) * | 1999-08-06 | 2001-03-28 | Mccormack Ltd | Composition for treating dentine hypersensitivity |
| US7323160B2 (en) | 1999-08-14 | 2008-01-29 | Teldent Ltd. | Method of treating a patient's teeth using fluoride releasing glass composition |
| IL135061A0 (en) | 2000-03-14 | 2001-05-20 | Ahron Jodaikin | Strategic targeted fluoridation and chemical treatment of teeth |
| US6558654B2 (en) | 2000-04-11 | 2003-05-06 | Mclaughlin Gerald | Composition and method for whitening teeth |
| JP2002097125A (en) | 2000-09-21 | 2002-04-02 | Hironori Oka | Teeth bleaching composition keeping natural teeth color |
| US20020081360A1 (en) | 2000-12-27 | 2002-06-27 | Andreas Burgard | Salts of L-amino acid having improved taste and their preparation |
| RU2238078C1 (en) | 2003-01-21 | 2004-10-20 | Чухаджян Ара Гарникович | Therapeutic and prophylactic topical-destination facility in the form of self-sticking film for remineralization of solid dental tissues |
| JP2005015435A (en) * | 2003-06-27 | 2005-01-20 | Sun Medical Co Ltd | Polymerizable composition and its polymer |
| US20050175552A1 (en) | 2004-02-10 | 2005-08-11 | Hoic Diego A. | Tooth coating compositions and methods therefor |
| DE602004009279T2 (en) * | 2004-03-05 | 2008-07-10 | Straumann Holding Ag | Manufacturing method of a dental device with injection molding |
| WO2006106838A1 (en) * | 2005-03-30 | 2006-10-12 | Kuraray Medical Inc. | Fluorine ion-releasable composition for dental purposes |
| CN101262796B (en) | 2005-07-12 | 2011-11-16 | 高露洁-棕榄公司 | Oral care implement having reservior for dispensing active agent |
| US20070238808A1 (en) * | 2006-03-09 | 2007-10-11 | Goldberg A J | Dental materials, methods of making and using the same, and articles formed therefrom |
| AU2007249542B2 (en) | 2006-05-09 | 2009-11-05 | Colgate-Palmolive Company | Oral care regimen |
| US8900558B2 (en) | 2006-06-30 | 2014-12-02 | Colgate-Palmolive Company | High fluoride ion oral care composition and method for maintaining anticaries activity |
| BRPI0906451B1 (en) | 2008-02-08 | 2017-01-24 | Colgate Palmolive Co | method to produce arginine bicarbonate |
-
2009
- 2009-02-06 BR BRPI0907103A patent/BRPI0907103A2/en not_active IP Right Cessation
- 2009-02-06 AU AU2009212339A patent/AU2009212339B2/en not_active Ceased
- 2009-02-06 MX MX2010007738A patent/MX2010007738A/en active IP Right Grant
- 2009-02-06 EP EP09708758.9A patent/EP2249764B1/en active Active
- 2009-02-06 JP JP2010544489A patent/JP2011510095A/en active Pending
- 2009-02-06 TW TW98103776A patent/TWI376237B/en not_active IP Right Cessation
- 2009-02-06 CA CA2711262A patent/CA2711262C/en not_active Expired - Fee Related
- 2009-02-06 CN CN2009801045327A patent/CN101938970A/en active Pending
- 2009-02-06 RU RU2010137322/15A patent/RU2493812C2/en not_active IP Right Cessation
- 2009-02-06 US US12/866,766 patent/US10391038B2/en active Active
- 2009-02-06 AR ARP090100435 patent/AR070589A1/en not_active Application Discontinuation
- 2009-02-06 WO PCT/US2009/033312 patent/WO2009100283A2/en active Application Filing
-
2010
- 2010-05-24 ZA ZA2010/03694A patent/ZA201003694B/en unknown
- 2010-09-03 CO CO10109377A patent/CO6241091A2/en not_active Application Discontinuation
-
2014
- 2014-01-06 JP JP2014000503A patent/JP2014088419A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0907103A2 (en) | 2016-05-03 |
| JP2014088419A (en) | 2014-05-15 |
| EP2249764A2 (en) | 2010-11-17 |
| AU2009212339B2 (en) | 2011-12-22 |
| TW201000143A (en) | 2010-01-01 |
| CN101938970A (en) | 2011-01-05 |
| WO2009100283A2 (en) | 2009-08-13 |
| RU2493812C2 (en) | 2013-09-27 |
| AR070589A1 (en) | 2010-04-21 |
| ZA201003694B (en) | 2014-11-26 |
| JP2011510095A (en) | 2011-03-31 |
| EP2249764A4 (en) | 2012-02-22 |
| CA2711262A1 (en) | 2009-08-13 |
| RU2010137322A (en) | 2012-03-20 |
| WO2009100283A3 (en) | 2009-11-12 |
| US20100316726A1 (en) | 2010-12-16 |
| AU2009212339A1 (en) | 2009-08-13 |
| US10391038B2 (en) | 2019-08-27 |
| MX2010007738A (en) | 2010-08-10 |
| TWI376237B (en) | 2012-11-11 |
| CO6241091A2 (en) | 2011-01-20 |
| EP2249764B1 (en) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2711262C (en) | Dental composition comprising a basic amino acid for alleviating tooth sensitivity | |
| US5849266A (en) | Dental composition for hypersensitive teeth | |
| AU2002240115B2 (en) | Topical oral care compositions | |
| AU2002240115A1 (en) | Topical oral care compositions | |
| US8303938B2 (en) | Anti-calculus dental composition | |
| RU2519329C2 (en) | Compositions and devices | |
| RU2455001C2 (en) | Compositions and methods of treating xerostomia | |
| CN101938984A (en) | Cleaning compositions and methods | |
| Iqbal et al. | Role of different ingredients of tooth pastes and mouthwashes in oral health | |
| EP0381445A2 (en) | Dental composition for hypersensitive teeth | |
| US10201482B2 (en) | Dual component oral composition for enhancing remineralization of teeth | |
| KR100308247B1 (en) | Compositions for cleaning oral cavity | |
| Kumar et al. | Advanced materials for prevention of calculus formation on enamel: A review | |
| JPH11240816A (en) | Composition for coating tooth | |
| EP4044995A1 (en) | Oral care composition | |
| WO2007078074A1 (en) | Mouthwash composition for the prevention of dental diseases | |
| Sohi et al. | Fresh Mouth is a Gateway to a Healthy Body–An Overview of Current Use of Chlorhexidine | |
| US20070292368A1 (en) | Oral care composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20190206 |
|
| MKLA | Lapsed |
Effective date: 20190206 |